Acumen Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ABOS$0.23-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses | ||||
| Research and development | $27,247 | $11,179 | $59,229 | $29,025 |
| General and administrative | 5,018 | 4,860 | 15,191 | 13,627 |
| Total operating expenses | 32,265 | 16,039 | 74,420 | 42,652 |
| Loss from operations | (32,265) | (16,039) | (74,420) | (42,652) |
| Other income (expense) | ||||
| Interest income | 3,504 | 3,124 | 11,325 | 6,840 |
| Interest expense | (1,027) | — | (3,031) | — |
| Change in fair value of embedded derivatives | (10) | — | 1,040 | — |
| Other income (expense), net | 33 | (42) | (89) | (62) |
| Total other income | 2,500 | 3,082 | 9,245 | 6,778 |
| Net loss | (29,765) | (12,957) | (65,175) | (35,874) |
| Other comprehensive gain (loss) | ||||
| Unrealized gain on marketable securities | 682 | 137 | 206 | 242 |
| Comprehensive loss | $(29,083) | $(12,820) | $(64,969) | $(35,632) |
| Net loss per common share, basic and diluted | $(0.50) | $(0.24) | $(1.09) | $(0.79) |
| Weighted-average shares outstanding, basic and diluted | 60,079,778 | 54,229,630 | 59,990,844 | 45,474,953 |
Condensed Statements of Changes in Stockholders’ Equity
(in thousands, except share data)
For the Three Months Ended September 30, 2024
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance as of June 30, 2024 | 60,079,778 | $6 | $502,313 | $(258,208) | $(164) | $243,947 | |||||
| Unrealized gain on marketable securities | — | — | — | — | 682 | 682 | |||||
| Stock-based compensation | — | — | 2,338 | — | — | 2,338 | |||||
| Net loss | — | — | — | (29,765) | — | (29,765) | |||||
| Balance as of September 30, 2024 | 60,079,778 | $6 | $504,651 | $(287,973) | $518 | $217,202 | |||||
For the Three Months Ended September 30, 2023
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveLoss · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance as of June 30, 2023 | 41,025,062 | $4 | $362,860 | $(193,344) | $(646) | $168,874 | |||||
| Issuance of common stock for cash, net of issuance costs of $7,706 | 16,774,193 | 2 | 122,292 | — | — | 122,294 | |||||
| Stock options exercised for cash | 111,206 | — | 325 | — | — | 325 | |||||
| Unrealized gain on marketable securities | — | — | — | — | 137 | 137 | |||||
| Stock-based compensation | — | — | 1,600 | — | — | 1,600 | |||||
| Net loss | — | — | — | (12,957) | — | (12,957) | |||||
| Balance as of September 30, 2023 | 57,910,461 | $6 | $487,077 | $(206,301) | $(509) | $280,273 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.